Clinical trial tracker

Clinical trial tracker

Looking for Lilly’s LY4086940? Its two registered trials, NCT06945419 and NCT07890376, are listed below. For what they test and what has not been disclosed, see the LY4086940 profile or our LY4086940 write-up.

Reset

134 registered trials, newest registry update first.

TrialCompoundPhaseStatusSponsorEnrolledPrimary completionRegistry updated
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
NCT01519349
Follistatin 344Phase 1CompletedNationwide Children's Hospital15Oct 2017Oct 2, 2023
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
NCT04881760
RetatrutidePhase 2CompletedEli Lilly and Company338May 16, 2022Sep 13, 2023
A Study of LY3457263 in Obese Participants
NCT05582096
NisotirostidePhase 1CompletedEli Lilly and Company38Jun 8, 2023Jul 18, 2023
A Study of LY3437943 in Participants With Type 2 Diabetes
NCT04867785
RetatrutidePhase 2CompletedEli Lilly and Company281Jul 8, 2022Jul 3, 2023
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
NCT04153929
SurvodutidePhase 2CompletedBoehringer Ingelheim413Oct 8, 2021Nov 29, 2022
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
NCT03569007
LarazotidePhase 3Terminated9 Meters Biopharma, Inc.307Jul 21, 2022Jul 26, 2022
Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
NCT01438073
Kisspeptin-10Phase 1CompletedMassachusetts General Hospital96Apr 2016Jul 11, 2022
Intratumoral Injections of LL37 for Melanoma
NCT02225366
LL-37Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center4Nov 24, 2020Dec 9, 2021
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
NCT03600480
Cagri-Sema, CagrilintidePhase 1CompletedNovo Nordisk A/S96Jun 12, 2020Nov 17, 2021
Oral LAT8881 in Neuropathic Pain
NCT03865953
AOD-9604Phase 2CompletedLateral Pharma Pty Ltd53Apr 19, 2020Jun 14, 2021
A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
NCT04153409
AOD-9604Phase 2CompletedLateral Pharma Pty Ltd21Feb 15, 2020Apr 28, 2021
A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers
NCT04555824
TB-500Phase 1CompletedBeijing Northland Biotech. Co., Ltd.54Feb 20, 2018Sep 29, 2020
A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers
NCT04555850
TB-500Phase 1CompletedBeijing Northland Biotech. Co., Ltd.30Feb 18, 2019Sep 29, 2020
Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147
NCT03838185
J-147Phase 1CompletedAbrexa Pharmaceuticals, Inc.64Feb 1, 2020Sep 3, 2020
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
NCT01262664
AdipotidePhase 1TerminatedM.D. Anderson Cancer Center4Jan 2, 2019Jan 4, 2019
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease
NCT00889473
LarazotidePhase 2Completed9 Meters Biopharma, Inc.42Nov 2009Sep 20, 2017
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
NCT01396213
LarazotidePhase 2Completed9 Meters Biopharma, Inc.342Aug 20, 2013Sep 20, 2017
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
NCT01925209
BimagrumabPhase 2 / Phase 3CompletedNovartis Pharmaceuticals251Jan 6, 2016Aug 11, 2017
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
NCT02039687
ARA-290Phase 2CompletedAraim Pharmaceuticals, Inc.64Jan 2015Apr 18, 2017
Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus
NCT00672074
IpamorelinPhase 2CompletedHelsinn Therapeutics (U.S.), Inc117Dec 2009Apr 14, 2017
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
NCT01280344
IpamorelinPhase 2CompletedHelsinn Therapeutics (U.S.), Inc320Jun 2013Apr 13, 2017
A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism
NCT02369796
Kisspeptin-10Phase 2TerminatedTakeda15Oct 2015Mar 31, 2017
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
NCT01167881
ATX-304Phase 3CompletedBoehringer Ingelheim1,549Aug 2013Sep 2, 2016
Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia
NCT01963598
TrevogrumabPhase 2CompletedRegeneron Pharmaceuticals253Jan 2015Mar 28, 2016
TH9507 in Patients With HIV-Associated Lipodystrophy
NCT00123253
TesamorelinPhase 3CompletedTheratechnologies412Nov 2006Nov 27, 2013
TH9507 in Patients With HIV-Associated Lipodystrophy
NCT00435136
TesamorelinPhase 3CompletedTheratechnologies412Nov 2006Nov 27, 2013
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study for Proof of Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
NCT00148486
TesofensinePhase 2CompletedBoehringer Ingelheim261Mar 2005Oct 29, 2013
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations
NCT00148512
TesofensinePhase 2CompletedBoehringer Ingelheim254Feb 2005Oct 29, 2013
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer’s Type
NCT00153010
TesofensinePhase 2CompletedBoehringer Ingelheim430Mar 2005Oct 29, 2013
Effect of Tesofensine on Weight Reduction in Patients With Obesity.
NCT00394667
TesofensinePhase 2CompletedNeuroSearch A/S200Not statedApr 22, 2013
Evaluation of Long Term Safety of Tesofensine in Patients With Obesity
NCT00481104
TesofensinePhase 2CompletedNeuroSearch A/S140Sep 2008Jul 4, 2011
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes
NCT00508287
ATX-304Phase 1CompletedBristol-Myers Squibb36Nov 2007Mar 16, 2009
Effect of Tesofensine on Energy Balance in Humans.
NCT00428415
TesofensinePhase 1 / Phase 2CompletedNeuroSearch A/S32Dec 2007Mar 5, 2008
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
NCT00267527
CJC-1295 with DACPhase 2TerminatedConjuChem120Not statedOct 16, 2006

← Newer Page 3 of 3

Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.